AI shake-up in cancer care: Can Agilent and Lunit redefine biomarker testing for investors?

Why did Agilent Technologies partner with Lunit to accelerate AI diagnostics in cancer care?

Agilent Technologies, Inc. (NYSE: A), a global leader in life sciences and diagnostics, has announced a non-exclusive partnership with Lunit, Inc. (KRX: 328130.KQ), one of South Korea’s most prominent artificial intelligence medical software firms, to co-develop AI-powered companion diagnostic solutions. The partnership combines Agilent’s expertise in tissue-based assays with Lunit’s advanced AI algorithms, designed to reshape the future of biomarker testing.

The collaboration comes as precision oncology continues to gain momentum worldwide. Spending on targeted oncology therapies and diagnostics is forecast to exceed 140 billion dollars annually by 2030. As new cancer treatments are developed, the demand for companion diagnostics that can accurately match patients to therapies is accelerating. This alliance is therefore well-timed, aligning with the sector’s strategic pivot toward AI integration.

Agilent reported more than 1.27 billion dollars in revenue from its diagnostics and genomics group in fiscal 2024, representing close to 20 percent of its total revenue. Lunit, meanwhile, has already scaled its AI suite into more than 65 countries, providing FDA-cleared and CE-marked tools used in over 7,000 hospitals and cancer centers. The combination of Agilent’s regulatory credibility and Lunit’s digital innovation creates a powerful equation for expansion.

How could AI-powered companion diagnostics transform biomarker testing in clinical trials?

Historically, biomarker testing has been reliant on manual interpretation, where tissue staining and slide reading by pathologists introduces subjectivity and inter-laboratory variability. This inconsistency can complicate the drug approval process, delay the launch of companion diagnostics, and slow the adoption of personalized treatments.

The integration of AI promises to eliminate much of this variability. By applying machine learning to biomarker interpretation, Agilent and Lunit aim to deliver results that are not only faster but also more reproducible. For pharmaceutical companies running clinical trials, this means better patient stratification, clearer efficacy data, and reduced risk of regulatory setbacks. For clinicians, it offers a more consistent diagnostic pathway, reducing the margin of error and improving treatment outcomes.

AI tools have already proven successful in radiology, particularly in breast cancer and lung cancer imaging, where algorithms have matched or even exceeded human performance. Extending this success into tissue-based diagnostics could make companion tests more reliable, accelerate drug development pipelines, and enhance confidence among regulators, payers, and clinicians.

What does the Agilent Technologies and Lunit collaboration mean for investor sentiment and stock performance?

Agilent Technologies’ stock has gained approximately 12 percent so far in 2025, comfortably ahead of the S&P 500 healthcare index’s eight percent growth. Institutional investors continue to show steady inflows into the stock, with short interest under two percent of the float. Analysts broadly rate Agilent between “Hold” and “Buy,” noting its strong lab instrumentation franchise but urging greater monetization of its diagnostics business.

The partnership with Lunit addresses that exact gap. Investors are likely to interpret this as a strategic step toward capturing a larger share of the precision oncology market. If successful, the collaboration could unlock new recurring revenues from pharma collaborations and assay licensing. Early market response has been cautiously optimistic, with minor upward movements in Agilent’s after-market trading following the announcement.

Lunit, listed on the Korea Exchange under ticker 328130.KQ, has surged more than 35 percent in 2025. Institutional participation from global biotech funds is rising, and the partnership with Agilent is expected to strengthen perceptions of Lunit as a global, not just regional, AI diagnostics leader. Retail participation remains significant, which may drive volatility, but sentiment has turned decisively positive after the announcement.

Which risks and challenges could limit the success of this AI diagnostic partnership in 2025 and beyond?

Despite its promise, the collaboration must navigate several hurdles. The regulatory environment for AI in companion diagnostics is still evolving. Regulators such as the FDA demand rigorous validation of reproducibility across diverse labs, patient populations, and staining techniques. Even if algorithms perform well, approvals could take longer than anticipated.

Commercialization is another challenge. While pharmaceutical companies in clinical trials may adopt AI-powered assays early, broader clinical use depends on reimbursement decisions. Payers will require evidence of cost-effectiveness and clinical utility before approving coverage, meaning Agilent and Lunit must demonstrate not only accuracy but also economic value.

The non-exclusive nature of the agreement also opens the door for rivals. Global players like Roche Diagnostics, Siemens Healthineers, and Philips are developing AI-driven diagnostic platforms of their own. Parallel partnerships may dilute the competitive advantage of Agilent and Lunit unless they can establish early leadership.

Finally, infrastructure readiness remains uneven. Hospitals worldwide vary in their digital maturity, and AI systems require standardized imaging, staining, and data-handling pipelines to function reliably. Integration costs and workflow changes may slow adoption even after regulatory approvals.

How does this alliance compare with other global moves in AI-driven precision medicine?

The Agilent–Lunit alliance is part of a wider competitive race in AI diagnostics. Roche’s acquisition of Foundation Medicine, Thermo Fisher Scientific’s investments in next-generation sequencing, and Illumina’s digital pathology initiatives highlight the industry’s consensus that diagnostics must evolve into digital-first platforms.

Agilent’s history of acquiring Dako in 2012 established its cancer diagnostics base, and this move can be viewed as an extension into the AI era. Unlike outright acquisitions, however, Agilent has opted for a non-exclusive collaboration, which minimizes risk but also limits exclusivity. For Lunit, the partnership with Agilent is particularly significant as it elevates its profile in Western markets, where regulatory approval and pharma partnerships carry higher credibility.

This East–West partnership also reflects a growing model in healthcare, where U.S. and European companies are collaborating with Asian AI innovators to accelerate digital transformation. It positions both companies strategically at the intersection of innovation, regulation, and market expansion.

What signals should institutional investors track from Agilent and Lunit in fiscal 2026?

For Agilent Technologies, investors should watch for references to this collaboration in fiscal 2026 guidance, especially if management begins attributing revenue to AI-enhanced diagnostics or clinical trial collaborations. Updates on regulatory validation and pharma adoption will be key catalysts.

For Lunit, milestones include the expansion of its AI suite into tissue-based diagnostics, securing additional partnerships with pharmaceutical companies, and attracting further foreign institutional inflows. Regulatory traction in the U.S. or Europe would provide strong validation.

Broadly, the partnership signals that AI is moving from pilot projects to mainstream integration in oncology diagnostics. If the alliance delivers tangible results within 12 to 18 months, it could become a model for similar cross-border partnerships and trigger further M&A or licensing activity in the sector.